{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:49Z","timestamp":1793041969290,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.clml.2023.01.017","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T12:57:55Z","timestamp":1675429075000},"page":"310-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["SOHO State-of-the-Art Updates and Next Questions | BCMA-Directed CAR T-Cells: Early Results and Future Directions"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-4079","authenticated-orcid":false,"given":"Eden","family":"Biltibo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.01.017_bib0001","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2023.01.017_bib0002","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.01.017_bib0003","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/164_2017_10","article-title":"Mechanisms of resistance in multiple myeloma","volume":"249","author":"Papadas","year":"2018","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.clml.2023.01.017_bib0004","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.01.017_bib0005","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2022-168843","article-title":"Real world data on outcomes of anti-CD38 antibody refractory, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) database","volume":"140","author":"Visram","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0006","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.017_bib0007","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2023.01.017_bib0008","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.017_bib0009","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1002\/j.1460-2075.1992.tb05482.x","article-title":"A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma","volume":"11","author":"La\u00e2bi","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.clml.2023.01.017_bib0010","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int Immunol"},{"key":"10.1016\/j.clml.2023.01.017_bib0011","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.192.1.129","article-title":"BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population","volume":"192","author":"Thompson","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2023.01.017_bib0012","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1084\/jem.192.11.1677","article-title":"A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth","volume":"192","author":"Rennert","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2023.01.017_bib0013","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0014","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.01.017_bib0015","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0016","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.01.017_bib0017","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.017_bib0018","first-page":"26","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0019","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2023.01.017_bib0020","doi-asserted-by":"crossref","unstructured":"Wang BY, Zhao WH, Lie J, et\u00a0al. Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). 2019;11:579.","DOI":"10.1182\/blood-2019-124953"},{"key":"10.1016\/j.clml.2023.01.017_bib0021","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.01.017_bib0022","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-140156","article-title":"Two-year follow-up of investigator-initiated phase 1 trials of the safety and efficacy of fully human anti-BCMA CAR T Cells (CT053) in relapsed\/refractory multiple myeloma","volume":"136","author":"Hao","year":"2020","journal-title":"Blood;"},{"key":"10.1016\/j.clml.2023.01.017_bib0023","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1182\/blood-2022-168610","article-title":"Phase \u2161 study of fully human BCMA-targeting CAR-T Cells (zevorcabtagene autoleucel) in patients with relapsed\/refractory multiple myeloma","volume":"140","author":"Chen","year":"2022","journal-title":"Blood;"},{"key":"10.1016\/j.clml.2023.01.017_bib0024","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2022.40.16_suppl.8003","article-title":"Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma","volume":"41","author":"Frigault","year":"2022","journal-title":"J Clin Oncol;"},{"key":"10.1016\/j.clml.2023.01.017_bib0025","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J Clin Oncol;"},{"key":"10.1016\/j.clml.2023.01.017_bib0026","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood-2022-160038","article-title":"Results from the first phase 1 clinical study of the B-Cell maturation antigen (BCMA) Nex T chimeric antigen receptor (CAR) T Cell therapy CC-98633\/BMS-986354 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0027","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated results from the phase I CRB-402 study of anti-BCMA CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T Cell phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0028","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood-2021-146518","article-title":"Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma","volume":"138","author":"Raje","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0029","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2019-129562","article-title":"Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME)","volume":"134","author":"Costello","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0030","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2021-151672","article-title":"Clinical trials of BCMA-targeted CAR-T cells utilizing a novel non-viral transposon system","volume":"138","author":"Costello","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0031","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-142695","article-title":"Phase 1\/2 study of the safety and response of P-BCMA-101 CAR-T Cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies","volume":"136","author":"Costello","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0032","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S2152-2650(22)00277-4","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed and refractory multiple myeloma: real-world experience","volume":"22","author":"Hansen","year":"2022","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2023.01.017_bib0033","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.01.017_bib0034","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1182\/blood-2022-162682","article-title":"French early nationwide idecabtagene vicleucel (Ide-Cel) chimeric antigen receptor (CAR) T-Cell Therapy experience in patients with relapsed\/refractory multiple myeloma (FENIX): an IFM study from the Descar-T registry","volume":"140","author":"Ferment","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134322","article-title":"Efficacy and safety of idecabtagene vicleucel (ide-cel, bb2121) in elderly patients with relapsed and refractory multiple myeloma: KarMMa subgroup analysis","volume":"136","author":"Berdeja","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0036","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S2152-2650(22)00281-6","article-title":"Efficacy and safety of BCMA-targeted CAR-T therapy in elderly patients with multiple myeloma","volume":"22","author":"Reyes","year":"2022","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2023.01.017_bib0037","doi-asserted-by":"crossref","first-page":"10377","DOI":"10.1182\/blood-2022-166058","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-Cell therapy for relapsed\/refractory multiple myeloma with renal insufficiency: real world experience","volume":"140","author":"Sidana","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0038","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1182\/blood-2022-165483","article-title":"Chimeric antigen receptor-T (CAR-T) cell therapy targeting BCMA in patients with prior allogeneic transplantation (allo-HCT) in relapsed and\/or refractory multiple myeloma (RRMM)","volume":"140","author":"Hammons","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0039","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clml.2021.10.013","article-title":"Comparison of Cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed\/refractory Multiple Myeloma","volume":"22","author":"Costa","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.01.017_bib0040","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.01.017_bib0041","first-page":"1","article-title":"Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice","author":"Mateos","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.01.017_bib0042","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","article-title":"Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"37","author":"Martin","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2023.01.017_bib0043","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/17474086.2022.2081147","article-title":"Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma","volume":"15","author":"Davis","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2023.01.017_bib0044","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2022-166658","article-title":"Early and sustained undetectable measurable residual disease (MRD) after idecabtagene vicleucel (ide-cel) defines a subset of multiple myeloma (MM) patients in KarMMa achieving prolonged survival","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0045","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1182\/blood-2022-159141","article-title":"Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1","volume":"140","author":"Munshi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0046","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood-2022-164884","article-title":"idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-Cell therapy in patients with relapsed\/refractory multiple myeloma (RRMM) who have received a prior BCMA-targeted therapy: real world, multi-institutional experience","volume":"140","author":"Ferreri","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0047","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1182\/blood-2022-164828","article-title":"Factors associated with refractoriness or early progression after idecabtagene vicleucel (Ide-cel) in patients with relapsed\/refractory multiple myeloma (RRMM): U.S. myeloma CAR T consortium real world experience","volume":"140","author":"Hashmi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0048","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0049","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2023.01.017_bib0050","first-page":"P867","article-title":"Tumor profiling of idecabtagene vicleucel (IDE-CEL; BB2121) patients in KarMMa showed comparable responses in existing molecular high-risk subsets and preliminary gene signature of durable response","volume":"6","author":"Martin","year":"2022","journal-title":"EHA Library"},{"key":"10.1016\/j.clml.2023.01.017_bib0051","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.HS9.0000829656.69351.86","article-title":"Subsequent anti-myeloma therapy after idecabtagene vicleucel (Ide-cel, BB2121) treatment in patients with relapsed\/refractory multiple myeloma from the KarMMa study","volume":"6","author":"Rodr\u00edguez-Otero","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2023.01.017_bib0052","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood-2022-160401","article-title":"Clinical outcomes and salvage therapies in patients with relapsed\/refractory multiple myeloma following progression on BCMA-targeted CAR-T therapy","volume":"140","author":"Reyes","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0053","doi-asserted-by":"crossref","unstructured":"Touzeau C, Krishnan AY, Moreau P, et\u00a0al. Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents. 2021;6:8013\u20138013.","DOI":"10.1200\/JCO.2022.40.16_suppl.8013"},{"key":"10.1016\/j.clml.2023.01.017_bib0054","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood-2022-166494","article-title":"Elranatamab, a BCMA targeted T-Cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma","volume":"140","author":"Raje","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0055","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2022-162469","article-title":"KarMMa-2 Cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation","volume":"140","author":"Usmani","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0056","doi-asserted-by":"crossref","first-page":"7536","DOI":"10.1182\/blood-2022-159169","article-title":"Ciltacabtagene autoleucel (Cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2 Cohort B 18-month follow-up","volume":"140","author":"Van De Donk","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0057","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2023.01.017_bib0058","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.017_bib0059","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2022-162395","volume":"140","author":"Bal","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0060","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/JCO.2022.40.16_suppl.8004","article-title":"Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed\/refractory multiple myeloma (POLARIS)","volume":"10","author":"Huang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.01.017_bib0061","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T Cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clml.2023.01.017_bib0062","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.clml.2023.01.017_bib0063","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2023.01.017_bib0064","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free sleeping beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther"},{"key":"10.1016\/j.clml.2023.01.017_bib0065","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.017_bib0066","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2022-159707","article-title":"Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): phase 1\/2 results from monumenTAL-1","volume":"140","author":"Chari","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0067","first-page":"157","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"140","author":"Trudel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0068","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0069","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1182\/blood-2022-158231","article-title":"Universal updated phase 1 data highlights role of allogeneic anti-BCMA ALLO-715 therapy for relapsed\/refractory multiple myeloma","volume":"140","author":"Mailankody","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0070","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2022.40.16_suppl.8005","article-title":"Updated results of a multicenter first-in-human study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM)","author":"Du","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.01.017_bib0071","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood-2022-162295","article-title":"Phase I open-label single-arm study of BCMA\/CD19 dual-targeting FasTCAR-T Cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma","volume":"140","author":"Du","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0072","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2023.01.017_bib0073","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1182\/blood-2019-126689","article-title":"Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T Cell targeting APRIL for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Popat","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0074","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2023.01.017_bib0075","series-title":"24th European Hematology Association Congress","article-title":"NKG2D and BCMA-CAR NK cells efficiently eliminate multiple myeloma cells. A comprehensive comparison between two clinically relevant CARs","author":"Maroto-Martin","year":"2019"},{"key":"10.1016\/j.clml.2023.01.017_bib0076","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.1182\/blood-2022-159289","article-title":"Allogeneic CAR-NK cell therapy targeting both BCMA and GPRC5D for the treatment of multiple myeloma","volume":"140","author":"Cao","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.017_bib0077","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fimmu.2016.00112","article-title":"Marrow-infiltrating lymphocytes - role in biology and cancer therapy","volume":"7","author":"Borrello","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2023.01.017_bib0078","doi-asserted-by":"crossref","first-page":"288ra78","DOI":"10.1126\/scitranslmed.aaa7014","article-title":"Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma","volume":"7","author":"Noonan","year":"2015","journal-title":"Sci Transl Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:12Z","timestamp":1761871332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2152265023000344"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State-of-the-Art Updates and Next Questions | BCMA-Directed CAR T-Cells: Early Results and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}